scispace - formally typeset
H

Hana Algül

Researcher at Technische Universität München

Publications -  180
Citations -  13430

Hana Algül is an academic researcher from Technische Universität München. The author has contributed to research in topics: Pancreatic cancer & Pancreatitis. The author has an hindex of 39, co-authored 155 publications receiving 10895 citations. Previous affiliations of Hana Algül include Ludwig Maximilian University of Munich & University of Ulm.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Talia Golan, +19 more
- 02 Jun 2019 - 
TL;DR: Among patients with a germline BRCA mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo, and there was no significant between-group difference in health-related quality of life.
Journal ArticleDOI

Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer.

Marina Lesina, +11 more
- 12 Apr 2011 - 
TL;DR: It is established that, in addition to oncogenic Kras(G12D), IL-6 transsignaling-dependent activation of Stat3/Socs3 is required to promote PanIN progression and pancreatic ductal adenocarcinoma (PDAC).
Journal ArticleDOI

Stromal biology and therapy in pancreatic cancer: a changing paradigm

Albrecht Neesse, +3 more
- 01 Sep 2015 - 
TL;DR: Recent data have shown that tumour-associated fibroblasts may restrain rather than promote tumour growth, reinforcing the need to critically revisit the complexity and complicity of the tumour–stroma with translational implications for future therapy and clinical trial design.
Journal ArticleDOI

Mutant KRAS -driven cancers depend on PTPN11 /SHP2 phosphatase

Dietrich A. Ruess, +26 more
- 28 May 2018 - 
TL;DR: The data indicate the clinical utility of dual SHP2/MEK inhibition as a targeted therapy approach for KRAS-mutant cancers and provide evidence for a critical dependence of mutant KRAS on SHp2 during carcinogenesis.